BridgeBio Pharma, Inc. (BBIO), a commercial-stage biopharmaceutical company, announced a voluntary agreement with the U.S. government to expand access to its marketed medicines and lower costs for American patients.
Under the agreement, BridgeBio will expand state Medicaid access to Attruby (acoramidis) through the GENEROUS model. Attruby is approved for adults with transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalization.
BridgeBio will continue to offer Attruby through Medicare Part D without future pricing mandates. The company said the agreement builds on its existing patient access efforts, including ForgingBridges, its patient support program that provides reimbursement navigation and financial assistance to qualifying patients, and potentially minimising costs.
Additionally, BridgeBio said it does not expect to be subject to future pricing mandates, while the specific terms of the agreement remain confidential.
The company also has three medicines under the FDA review, each a genetic condition with limited or no approved treatment options. Namely, BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), Encaleret for autosomal dominant hypocalcemia type 1 (ADH1), and Infigratinib for achondroplasia.
BBIO closed Tuesday's trade at $76.57, down 0.03%. In the after-hours trading, the stock is up 0.56% at $77.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.